Careers  |  Sign In  |  Register

RCC Content Hub

Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCC

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses side effects associated with the novel HIF-2α inhibitor, MK-6482, for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma (RCC). Dr. Jonasch explains 86.9% of patients experienced primarily grade 1 or 2 anemia, which often improved without treatment; however, a few patients required exogenous EPO treatment. The second most common side effect was fatigue, which Dr. Jonasch suggests may not be a true side effect.

Click here to learn more.